Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
|
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF INTERVENTIONAL LIVER-DIRECTED THERAPIES FOR EARLY STAGE HEPATOCELLULAR CARCINOMA IN LIVER TRANSPLANT CANDIDATES
    Wu, Xiao
    Heller, Michael
    Kwong, Allison J.
    Fidelman, Nicholas
    Mehta, Neil
    HEPATOLOGY, 2021, 74 : 628A - 629A
  • [2] Cost-effectiveness analysis of interventional liver-directed therapies for downstaging of HCC before liver transplant
    Wu, Xiao
    Kwong, Allison
    Heller, Michael
    Lokken, R. Peter
    Fidelman, Nicholas
    Mehta, Neil
    LIVER TRANSPLANTATION, 2024, 30 (02) : 151 - 159
  • [3] New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma
    Dalzell, Christina G.
    Taylor, Amy C.
    White, Sarah B.
    CANCERS, 2023, 15 (24)
  • [4] Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
    Kis, Bela
    El-Haddad, Ghassan
    Sheth, Rahul A.
    Parikh, Nainesh S.
    Ganguli, Suvranu
    Shyn, Paul B.
    Choi, Junsung
    Brown, Karen T.
    CANCER CONTROL, 2017, 24 (03)
  • [5] Liver-directed therapy for hepatocellular carcinoma
    Narsinh, Kazim H.
    Duncan, David P.
    Newton, Isabel G.
    Minocha, Jeet
    Rose, Steven C.
    ABDOMINAL RADIOLOGY, 2018, 43 (01) : 203 - 217
  • [6] Liver-directed therapy for hepatocellular carcinoma
    O'Leary, Cathal
    Mahler, Mary
    Soulen, Michael C.
    CHINESE CLINICAL ONCOLOGY, 2021, 10 (01)
  • [7] Liver-Directed Radiotherapy for Hepatocellular Carcinoma
    Keane, Florence K.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Hong, Theodore S.
    LIVER CANCER, 2016, 5 (03) : 198 - 209
  • [8] Liver-directed therapy for hepatocellular carcinoma
    Kazim H. Narsinh
    David P. Duncan
    Isabel G. Newton
    Jeet Minocha
    Steven C. Rose
    Abdominal Radiology, 2018, 43 : 203 - 217
  • [9] Imaging for Interventional Radiology Liver-Directed Therapies for Neuroendocrine Liver Metastases
    Kumari, Divya
    de Bruyn, Elise
    Al-Qawasmi, Faisal
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2024, 41 (03) : 270 - 277
  • [10] Cost analysis of tumor downsizing for hepatocellular carcinoma liver transplant candidates
    De Simone, P.
    Vignali, C.
    Petruccelli, S.
    Carrai, P.
    Coletti, L.
    Montin, U.
    Catalano, G.
    Urbani, L.
    Filipponi, F.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) : 3561 - 3563